Overview

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To describe the clinical response rate in two groups (Docetaxel plus cisplatin plus 5-FU, versus Cisplatin plus 5-FU) after 3 cycle of neoadjuvant chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Docetaxel